Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression.
Company Details
- Employees
- 24
- Address
- Berkeley, California, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.renasantbio.com
- HQ
- Berkeley, California
Renasant Bio Questions
Renasant Bio's website is http://www.renasantbio.com
Renasant Bio's LinkedIn profile is https://www.linkedin.com/company/renasant-bio
Renasant Bio has
24 employees.
View email and phone details for 24
employees at Renasant Bio.
Renasant Bio's industry is
Biotechnology Research
Renasant Bio's top competitors are
4:59 Newco, A 5am Ventures Company,
Evolutia Bio,
Darya Pharmaceuticals,
Byte51data,
Nuclidium Ag,
Varda Space Industries,
Centivax,
Actithera,
Kalvista Pharmaceuticals, Inc.,
5am Ventures.
Renasant Bio's categories are Biotechnology Research
